Back to Search Start Over

Formulations for Allergen Immunotherapy in Human and Veterinary Patients: New Candidates on the Horizon.

Authors :
Pali-Schöll I
DeBoer DJ
Alessandri C
Seida AA
Mueller RS
Jensen-Jarolim E
Source :
Frontiers in immunology [Front Immunol] 2020 Aug 04; Vol. 11, pp. 1697. Date of Electronic Publication: 2020 Aug 04 (Print Publication: 2020).
Publication Year :
2020

Abstract

Allergen immunotherapy is currently the only causal treatment for allergic diseases in human beings and animals. It aims to re-direct the immune system into a tolerogenic or desensitized state. Requirements include clinical efficacy, safety, and schedules optimizing patient or owner compliance. To achieve these goals, specific allergens can be formulated with adjuvants that prolong tissue deposition and support uptake by antigen presenting cells, and/or provide a beneficial immunomodulatory action. Here, we depict adjuvant formulations being investigated for human and veterinary allergen immunotherapy.<br /> (Copyright © 2020 Pali-Schöll, DeBoer, Alessandri, Seida, Mueller and Jensen-Jarolim.)

Details

Language :
English
ISSN :
1664-3224
Volume :
11
Database :
MEDLINE
Journal :
Frontiers in immunology
Publication Type :
Academic Journal
Accession number :
32849594
Full Text :
https://doi.org/10.3389/fimmu.2020.01697